CoChat

sTREM2 is associated with amyloid‐related p‐tau increases and glucose hypermetabolism in Alzheimer's disease

Open access
Biel, Davina, Suárez‐Calvet, Marc, Hager, Paul, Rubinski, Anna, Dewenter, Anna, Steward, Anna, Roemer, Sebastian, Ewers, Michael, Haass, Christian, Brendel, Matthias, Franzmeier, Nicolai, the Alzheimer's Disease Neuroimaging Initiative (ADNI) · 2023 · EMBO Molecular Medicine
Cited by 54

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

Abstract Microglial activation occurs early in Alzheimer's disease (AD) and previous studies reported both detrimental and protective effects of microglia on AD progression. Here, we used CSF sTREM2 to investigate disease stage‐dependent drivers of microglial activation and to determine downstream consequences on AD progression. We included 402 patients with measures of earliest beta‐amyloid (CSF Aβ 1‐42 ) and late‐stage fibrillary Aβ pathology (amyloid‐PET centiloid), as well as sTREM2, p‐tau 181 , and FDG‐PET. To determine disease stage, we stratified participants into early Aβ‐accumulators (Aβ CSF+/PET−; n = 70) or late Aβ‐accumulators (Aβ CSF+/PET+; n = 201) plus 131 controls. In early Aβ‐accumulators, higher centiloid was associated with cross‐sectional/longitudinal sTREM2 and p‐tau 181 increases. Further, higher sTREM2 mediated the association between centiloid and cross‐sectional/longitudinal p‐tau 181 increases and higher sTREM2 was associated with FDG‐PET hypermetabolism. In late Aβ‐accumulators, we found no association between centiloid and sTREM2 but a cross‐sectional association between higher sTREM2, higher p‐tau 181 and glucose hypometabolism. Our findings suggest that a TREM2‐related microglial response follows earliest Aβ fibrillization, manifests in inflammatory glucose hypermetabolism and may facilitate subsequent p‐tau 181 increases in earliest AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.202216987

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 54

Metadata

Authors
Biel, D., Suárez‐Calvet, M., Hager, P., Rubinski, A., Dewenter, A., Steward, A., Roemer, S., Ewers, M., Haass, C., Brendel, M., Franzmeier, N., & (ADNI), T. A. D. N. I.
Venue
EMBO Molecular Medicine
Published
2023-01-09
Volume
15
Issue
2
Pages
e16987-e16987
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W4313824861
Cited by
54
References
41
FWCI
4.48
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: sTREM2 is associated with amyloid‐related p‐tau increases and glucose hypermetabolism in Alzheimer's disease. https://app.cochat.ai/papers/10.15252/emmm.202216987
The paper
Biel, D., Suárez‐Calvet, M., Hager, P., Rubinski, A., Dewenter, A., Steward, A., Roemer, S., Ewers, M., Haass, C., Brendel, M., Franzmeier, N., & (ADNI), T. A. D. N. I. (2023). sTREM2 is associated with amyloid‐related p‐tau increases and glucose hypermetabolism in Alzheimer's disease. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202216987

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.